Quick Answer
Prime Medicine, Inc. reported Stockholders Equity of $120.87 million for fiscal year 2025.
Prime Medicine, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $120.87M | -21.1% |
| 2024 | $153.15M | +15.1% |
| 2023 | $133.07M | -57.9% |
| 2022 | $316.27M | +302.4% |
| 2021 | -$156.24M | -6782.6% |
| 2020 | $2.34M | +190.0% |
| 2019 | -$2.60M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $161.82M | -14.6% | +165.9% |
| June 30, 2025 | $60.86M | -69.0% | -43.1% |
| March 31, 2025 | $106.92M | -56.1% | -30.2% |
| December 31, 2024 | $153.15M | +15.1% | -19.2% |
| September 30, 2024 | $189.50M | -2.3% | -3.6% |
| June 30, 2024 | $196.59M | -18.1% | -19.4% |
| March 31, 2024 | $243.77M | -12.6% | +83.2% |
| December 31, 2023 | $133.07M | -57.9% | -31.4% |
- Prime Medicine, Inc. showed a decrease of -21.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Prime Medicine, Inc.’s stockholders equity has grown by 4752.3% (from -$2.60 million to $120.87 million).
- The most recent figure is from Prime Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: